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Severe Central Sleep Apnea in Vici Syndrome 
Abstract: 
Vici Syndrome is a rare congenital multisystem disorder due to recessive mutations in the key 
autophagy regulator EPG5. Vici syndrome is characterized by agenesis of the corpus callosum, 
hypopigmentation, immunodeficiency, cataracts and cardiomyopathy, with variable additional 
multisystem involvement. Here we report a 5-year-old girl presenting with global developmental 
delay, seizures, callosal agenesis, cataracts, sensorineural hearing loss, hypopigmentation, and 
immunodeficiency with low CD4 count and recurrent infections. EPG5 sequencing (prompted by 
suggestive clinical features) revealed a homozygous missense mutation, c.1007A>G; 
p.Gln336Arg. 
 The patient was referred to our center for evaluation of nocturnal apnea. Overnight 
polysomnography showed severe central sleep apnea (CSA) with an overall apnea-hypopnea 
index of 100.5 events per hour of sleep (central apnea index of 97.5, mixed apnea index of 2, and 
obstructive hypopnea index of 1). The patient responded to bi-level positive airway pressure 
therapy with a backup rate with normalization of the apnea-hypopnea index, and maintenance of 
oxygen saturation above 90%. Despite successful control of the severe CSA, the patient was 
eventually started on nocturnal oxygen therapy due to excessive upper airway secretions and the 
high risk of possible aspiration with positive airway pressure therapy. This is the first report of 
EPG5-related Vici syndrome associated with CSA. We discuss the polysomnographic findings in 
our patient in the context of a brief literature review of the reported sleep abnormalities in Vici 
syndrome. 
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Introduction: 
Vici syndrome (OMIM 242840) is a rare congenital syndrome with extensive multisystem 
involvement due to recessive mutations in EPG5 on chromosome 18q12.3, encoding the key 
autophagy regulator ectopic P-granules protein 5 (EPG5).1Vici syndrome was originally 
described in 1988 by Dionisi-Vici et al. in two brothers but with less than 30 cases reported to 
date, the phenotypical spectrum is still evolving .1-3 
Case Report: 
A 5-year-old girl diagnosed with Vici syndrome presented to our sleep center for evaluation of 
frequent short episodes of witnessed non-life-threatening nocturnal apnea. She was born via 
Cesarean section at 37 weeks’ gestation to consanguineous first cousin parents. Delivery was 
complicated by meconium aspiration. Birth weight was 2.27 kg (<3rd percentile), length was 49.5 
cm (57th percentile), and occipital frontal circumference was 34.3 cm (62nd percentile). She had a 
history of global developmental delay, seizures, bilateral cataracts, sensorineural hearing loss, 
biopsy-proven myopathy, and immunodeficiency with low CD4 count complicated by recurrent 
respiratory infections. She also had a transient dilated cardiomyopathy during an acute illness at 
the age of one year. Her mother had a history of obstructive sleep apnea and two first trimester 
spontaneous abortions; an older sibling was healthy. 
Previous investigations included analysis of the oculocutaneous albinism type 2 (OCA2) gene, 
revealing no mutations, and an examination of peripheral blood smears, requested under the 
suspicion of Chediak-Higashi syndrome but not showing any of the giant neutrophil granules 
suggestive of the latter. Brain magnetic resonance imaging (MRI) showed findings consistent 
with Vici syndrome, including agenesis of corpus callosum, colpocephaly, and atrophy of the 
optic nerves, pons, medulla, cerebellum, and cerebral hemispheres (Figure 1). Further genetic 
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testing prompted by suggestive clinical features revealed homozygosity for the EPG5 
c.1007A>G; p.Gln336Arg missense mutation, previously reported by Cullup et al.1 Key clinical 
and genetic features from our patient have been previously reported.1 
On examination at presentation to our center, height was 104 cm (22nd percentile) and weight 
was 15.5 kg (13th percentile). She did have no speech. There was generalized hypotonia and she 
couldn’t walk or sit without support. She had evidence of generalized hypopigmentation of the 
eyes, hair, and skin (Figure 2). She had a gastrostomy tube in place because of feeding 
difficulties. Oral examination revealed a normal tongue, Mallampati class IV, grade 2 tonsils, 
and a high arched palate with no micrognathia or maxillary retrusion. 
The patient underwent an overnight diagnostic polysomnography (PSG) (Table 1) using 
Respironics Alice system (Pittsburgh, PA). The PSG and sleep associated events were scored 
according to American Academy of Sleep Medicine (AASM) scoring guidelines.4 The patient 
had a total of 769 events including 746 central apneas, 15 mixed apneas, and 8 hypopneas with 
an overall apnea hypopnea index (AHI) of 100.5 events per hour of sleep (central apnea index of 
97.5, mixed apnea index of 2, and obstructive hypopnea index of 1) (Figure 3). 
Minimum oximetry value was 54% and the total time spent with O2 saturation below 89% was 
111.7 minutes. Transcutaneous carbon dioxide monitoring showed a mean PaCo2 of 46 mmHg. 
The PaCo2 was elevated above 50mmHg for almost 20% of the total sleep time (TST). The 
patient was not receiving any narcotics and her cardiac echocardiography showed normal cardiac 
anatomy and function with no evidence of pulmonary hypertension. High resolution chest CT 
showed no evidence of interstitial lung disease. 
Subsequently, the patient underwent an overnight titration study (Table 1). At bi-level PAP 
settings of 14/7 cmH2O in spontaneous/timed mode with a backup rate of 12 breaths per minute 
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the apnea hypopnea and arousal indices were normalized, and oxygen saturation was maintained 
above 90%. It was difficult for the patient to use positive airway pressure therapy due to 
excessive upper airway secretions, despite treatment with Glycopyrrolate, and the high risk of 
aspiration. After extensive discussion with the parents and considering the patient’s overall 
prognosis, a palliative management approach was chosen, including nocturnal oxygen at 1.5 
liters per minutes to keep her saturation above 90%. Unfortunately, our patient passed away at 
the age of 6 years as a consequence of recurrent infections. An autopsy was not performed. 
Discussion: 
Vici syndrome is a rare and severe congenital multisystem disorder with markedly reduced life 
expectancy. In the largest cohort study of Vici syndrome patients with confirmed EPG5 
mutations, only half of them were alive at the time of the last follow up.1The most common 
identifiable causes of death were progressive cardiac failure and recurrent infections secondary 
to the associated combined immunedeficiency.1 
Sleep abnormalities in Vici syndrome remain to be elucidated. Actigraphy and PSG were 
performed in two siblings with Vici syndrome. The actogram demonstrated a delay in the 
circadian rhythm in one patient possibly due to severe visual impairment. The PSG in both 
patients showed impaired phasic REM sleep parameters in setting of preserved percentage of 
REM sleep, and increased muscle atonia during NREM sleep. In both patients the brain MRI 
showed corpus callosum agenesis, mild cerebral atrophy, and opercular hypoplasia but no brain 
stem lesions.5 
In patients with Vici syndrome, the reported facial abnormalities, hypotonia, and laryngomalacia 
can all predispose to obstructive sleep apnea (OSA).6 Despite these reported anomalies, only one 
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case of Vici syndrome with OSA and mild desaturations was described. The patient’s brain MRI 
showed corpus callosum agenesis, pontine and cerebellar hypoplasia.7 
To our knowledge, this is the first case of Vici syndrome featuring CSA. Severe neurological 
involvement that included both the pons and medulla in our patient, evidenced by brain MRI, is a 
plausible cause in the pathogenesis of the central sleep apnea but the exact mechanism cannot be 
extrapolated from a single case. Besides absence of corpus callosum, additional central nervous 
system abnormalities were reported in 19 out of 27 patients diagnosed with Vici syndrome. 
These abnormalities included cerebellar and pontine hypoplasia, ventricular dilatation with white 
matter atrophy, heterotopias, abnormal septum pellucidum, and schizencephaly. (1,3) In absence of 
sleep studies in most of the Vici syndrome patients reported, sleep related breathing disorders 
including CSA cannot be excluded. 
Although the awake respiratory rate was lower than expected for age, our patient maintained 
awake PaCo2 level below 50mmHg with no elevation of serum bicarbonate levels. During sleep, 
there was further reduction of the respiratory rate with periods of hypercapnia. Although this can 
represent an element of sleep related hypoventilation, the total duration spent with PaCo2 above 
50mmHg was less than 25% of the TST which is required to score pediatric sleep related 
hypoventilation according to AASM scoring guidelines.4 
Another observation was the predominance of stage N3 non-rapid eye movement. Our patient 
spent 98.8% and 96.8% of her TST in stage N3 non-rapid eye movement during the diagnostic 
and the titration studies, respectively. Subjects with corpus callosum agenesis tend to have more 
slow-wave sleep, less inter-hemispheric electroencephalography coherence, and ultradian rhythm 
disturbances.8 Despite these findings in acallosal subjects, slow-wave sleep predominance was 
not described before among the polysomnographic findings in Vici syndrome.5,7 
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Although our patient was not receiving any REM sleep-suppressant medications, she did not 
have any REM sleep either during the diagnostic or the titration study. It is plausible that the 
absence of REM sleep in our patient could have been related to her pontine atrophy, considering 
that the pons plays an essential role in generation of REM sleep during which the central nervous 
system (CNS) cholinergic activity predominates. 9 Absence of REM sleep may suggest an 
impairment of CNS cholinergic system as well. Although REM sleep percentage was reported to 
be preserved in two siblings with Vici syndrome, both of them did not have evidence of brain 
stem involvement on brain MRI in contrast to our patient.5 
Pitt–Hopkins syndrome and familial agenesis of the corpus callosum are two conditions in which 
apneic spells were described in association with callosal agenesis. In both syndromes there was 
evidence of respiratory rhythm disturbances. 10,11 In Pitt–Hopkins syndrome the apneic spells 
were confirmed to be central apneas via polygraphic recording in one patient who did not have 
signs of brain stem abnormalities on imaging.10 In familial callosal agenesis, the apneic spells 
were clinically described and postmortem examination showed marked brain stem spongiosis, 
among other findings. 11 The apneic spells in these syndromes can be related to episodes of 
hyperventilation (post-hyperventilation apnea) in Pitt-Hopkins syndrome or to brain stem 
involvement in familial callosal agenesis.10, 11 Although animal studies suggest a possible role for 
the corpus callosum in functional integration of respiratory centers on both sides, the clinical 
implication of this observation in acallosal subjects is yet to be elucidated.12 
The potential for CSA to worsen heart failure in Vici syndrome patients with undiagnosed 
central apneas is not to be underestimated. The pathophysiological consequences of CSA 
adversely affect left ventricular structure, function and can worsen heart failure via several 
mechanisms that include increasing expression of pro-inflammatory and vasoconstrictor genes, 
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augmenting nocturnal sympathetic activity, and via changes in intra-thoracic pressure that can 
increase the afterload and oxygen consumption on an already compromised left ventricle. (13-16) 
Although there are short-term suggestions that treatment of CSA might improve cardiac 
function, there are however no robust studies to show the long term impact of treatment, 
particularly in children with rare disorders. 
In conclusion, we describe the first case of CSA associated with EPG5-related Vici syndrome. 
Our observation suggests that in addition to the associated cardiomyopathy and combined 
immunodeficiency, CSA has to be considered as another important and potentially treatable 
cause of morbidity and mortality in EPG5-related Vici syndrome.  More studies are needed to 
further investigate sleep abnormalities in EPG5-related Vici syndrome and their consequences. 
Finally, our observations suggest an intriguing link between certain sleep disorder phenotypes 
and neurodevelopmental disorders involving structural abnormalities of the corpus callosum and 
the pons.   
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Figure1: 
Brain MRI sagittal T1-weighted images show agenesis of corpus callosum (A; arrow), 
colpocephaly (B; *), and marked atrophy of pons, medulla, cerebellum and cerebral hemispheres. 
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Figure 2:  
The patient at the age of 3 years. (Consent was obtained from the parents) 
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Table1: Sleep architecture during the diagnostic and the titration study 
Parameter Diagnostic study Titration study 
Recording time (min) 520 486 
Total sleep time (TST) (min) 459 411.5 
Sleep efficiency (%) 88 84 
Sage N1 (%) 0 0 
Stage N2 (%) 0.8 3.2 
Stage N3 (%) 98.9 96.8 
Stage REM (%) 0 0 
Highest tcpco2* 59mmHg 46mmHg 
*tcpco2, transcutaneous carbon dioxide 
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Figure 3:  
A 2-minute polysomnographic recording during stage N3 non-rapid eye movement shows central 
apneas (red arrows) (transcutaneous PaCo2 shows PaCo2 levels below 50mmHg). 
 
 
 
 
 
 
